VP of Business Development, page-11

The most imperative matter at hand is that Prana Biotech has been a veritable do-nothing and asset-losing company for more than two years, since Prana announced the failure of PBT2 for AD at the end of Phase II. The new unannounced VP of Business Development, if she indeed was "hired" for more than to attend Pitch & Partner, will have a real challenge to convince future prospects of Prana's ability as a going concern and of the value of the inactive PBT2 and pipeline.

If the VP of Business Development is worth her salt she would immediately insist upon stopping Prana's lack of execution and communication for the sake of future business development. There is no explanation to the public of why requested information was not given to the FDA last year so that Huntington's Phase III could begin. That would be one of the primary issues that she would have to deal with when speaking to future business prospects: What is Prana hiding? If it isn't hiding anything, why isn't it moving?

The FDA wants information to help them make a decision of PBT2's safety. Prana has been glibly stating for years that PBT2 is safe but can't supply proof of safety in a reasonable amount of time. Something is drastically wrong; something that Prana is not telling us - especially the actual reason that the FDA questioned PBT2's safety in the first place. No news is not good news.